title: Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
abstract: Castration resistant prostate cancer (CRPC) treatment has been revolutionized over the past few years by the approval of novel therapies including cabazitaxel, sipuleucel-T, abiraterone and enzalutamide. Though androgen deprivation and chemotherapy remain the main therapeutic approaches for this disease, a series of targeted agents is also in development for the treatment of CRPC. Tasquinimod is a quinolone-3-carboxamide with antiangiogenic and antitumor activity in preclinical models of prostate cancer. A recent Phase II trial with this agent has demonstrated a significant clinical activity in asymptomatic or minimally symptomatic, chemotherapy-naïve, CRPC patients. A confirmatory Phase III trial of tasquinimod in prostate cancer is underway. Because of its antiangiogenic and immunomodulatory properties tasquinimod represents a novel targeted therapy with a unique mechanism of action.
authors: Genitorurinary Program, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. Saby.George@RoswellPark.org
authors: Saby
authors: S
authors: George
authors: Roberto
authors: R
authors: Pili
mesh_terms: D000230:Adenocarcinoma / Q000098:blood supply / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D008297:Male; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D015363:Quinolones; D016032:Randomized Controlled Trials as Topic; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011804:Quinolines; D015363:Quinolones; C516109:tasquinimod